BuybackMay 11, 2026, 06:36 AM
GSK announces final £0.18B tranche of £2B share buyback
AI Summary
GSK plc announced the commencement of the fifth and final tranche of its £2 billion share buyback programme. This final tranche, valued at up to approximately £0.18 billion, will enable the company to complete the previously announced programme. To date, GSK has repurchased shares worth approximately £1.82 billion, and the final tranche is expected to run from May 11, 2026, to June 26, 2026, with Citigroup Global Markets Limited acting as the agent. The programme's purpose is to return excess capital to shareholders and reduce share capital, which is expected to enhance earnings per share.
Key Highlights
- GSK announces the fifth and final tranche of its £2 billion share buyback programme.
- The final tranche is for up to approximately £0.18 billion.
- To date, GSK has repurchased 114,436,378 Ordinary Shares for approximately £1.82 billion.
- The final tranche is expected to commence on May 11, 2026, and complete by June 26, 2026.
- Citigroup Global Markets Limited will execute the final tranche independently.
- The programme aims to return excess capital to shareholders and enhance earnings per share.
- Shares purchased will be held as Treasury shares.
- The buyback is within GSK's existing authority granted at its 2026 AGM.